Navidea biopharmaceuticals informs stockholders of key dates and terms related to announced rights offering

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today provided an informational update to stockholders regarding its proposed rights offering and the expected key dates and terms relative to the offering. stockholders of record on august 3, 2022 (the “record date”) will be entitled to participate in the rights offering. prospective
NAVB Ratings Summary
NAVB Quant Ranking